EXTON, Pa., Sept. 9, 2013 /PRNewswire/ -- ViroPharma
Incorporated (Nasdaq: VPHM) today announced that the company will
present at the Stifel Nicolaus 2013 Healthcare Conference at
8:35 AM ET on Wednesday September 11, 2013. The
conference is being held at the Four Seasons Hotel in Boston.
ViroPharma's presentation will be webcast live for investors
through www.viropharma.com and available for a period of 14
days following the conference.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical
company committed to developing and commercializing novel solutions
for physician specialists to address unmet medical needs of
patients living with diseases that have few if any clinical
therapeutic options. ViroPharma is developing a portfolio of
therapeutics for rare and Orphan diseases including C1 esterase
inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia,
eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal
is to provide rewarding careers to employees, to create new
standards of care in the way serious diseases are treated, and to
build international partnerships with the patients, advocates, and
health care professionals we serve. ViroPharma's commercial
products address diseases including hereditary angioedema (HAE),
seizures in children and adolescents, adrenal insufficiency and
C. difficile-associated diarrhea (CDAD). For full U.S.
prescribing information on our products, please download the
package inserts at http://www.viropharma.com/Products.aspx; the
prescribing information for other countries can be found at
www.viropharma.com.
ViroPharma routinely posts information, including press
releases, which may be important to investors in the investor
relations and media sections of our company's web site,
www.viropharma.com. The company encourages investors to consult
these sections for more information on ViroPharma and our
business.
SOURCE ViroPharma Incorporated